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Background: Nationally, symptomatic heart failure affects 1.5-2% of Canadians, incurs $3 billion in hospital costs
annually and the global burden is expected to double in the next 1–2 decades. The current one-year mortality rate
after diagnosis of heart failure remains high at >25%. Consequently, new therapeutic strategies need to be
developed for this debilitating condition.
Methods/Design: The objective of the Alberta HEART program (http://albertaheartresearch.ca) is to develop novel
diagnostic, therapeutic and prognostic approaches to patients with heart failure with preserved ejection fraction.
We hypothesize that novel imaging techniques and biomarkers will aid in describing heart failure with preserved
ejection fraction. Furthermore, the development of new diagnostic criteria will allow us to: 1) better define risk
factors associated with heart failure with preserved ejection fraction; 2) elucidate clinical, cellular and molecular
mechanisms involved with the development and progression of heart failure with preserved ejection fraction; 3)
design and test new therapeutic strategies for patients with heart failure with preserved ejection fraction.
Additionally, Alberta HEART provides training and education for enhancing translational medicine, knowledge
translation and clinical practice in heart failure. This is a prospective observational cohort study of patients with, or
at risk for, heart failure. Patients will have sequential testing including quality of life and clinical outcomes over 12
months. After that time, study participants will be passively followed via linkage to external administrative
databases. Clinical outcomes of interest include death, hospitalization, emergency department visits, physician
resource use and/or heart transplant. Patients will be followed for a total of 5 years.
Discussion: Alberta HEART has the primary objective to define new diagnostic criteria for patients with heart failure
with preserved ejection fraction. New criteria will allow for targeted therapies, diagnostic tests and further
understanding of the patients, both at-risk for and with heart failure.
Trial registration: ClinicalTrials.gov NCT02052804.
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Cardiovascular disease is one of the primary causes of
death and disability in Canada and is a leading cause of
death worldwide (http://www.who.int/chp/chronic_disea-
se_report/en/). While advancements in medical and surgi-
cal therapies have improved cardiac mortality, these
advances have led to an increase in the incidence and
prevalence of heart failure (HF) [1]. At the national level,
symptomatic HF affects 1.5-2% of Canadians, incurs $3
billion in hospital costs annually, and the global burden is
expected to double in the next 1–2 decades [2,3]. In
addition, the current one-year mortality rate after diag-
nosis of HF remains disturbingly high at >25% [4,5], and
the condition has the worst effect on quality of life of
any chronic medical condition [6]. Consequently, new
therapeutic strategies need to be developed for this de-
bilitating condition.
HF is a clinical syndrome characterized by specific
symptoms (e.g. shortness of breath and reduced exer-
cise capacity) as well as physical examination findings.
HF has traditionally been described by a depressed ejec-
tion fractions ranging from <30-45% with <40% used as
a criteria that is generally used in clinical trials and
guidelines [7-9]. However, up to 50% of patients pre-
senting with HF have preserved systolic function and
are thus diagnosed with “diastolic HF” [3,10,11]. It is
now recognized that a diverse group of cardiac diseases
give rise to this condition and thus the clinical and re-
search community has more appropriately renamed
“diastolic HF” as HF with a preserved ejection fraction
(HF-PEF) or HF-preserved systolic function (HF-PSF).
Regardless of the nomenclature, no therapy has been
proven in randomized clinical trials to reduce the morbid-
ity or mortality of HF-PEF and, as such, no guideline en-
dorses a specific therapy targeted at HF-PEF [8,9,12,13].
While the lack of an available agent is multi-factorial, we
believe that the current criteria used for defining HF-PEF
are inadequate. This may skew patient stratification in HF
trials and prevent the identification of therapies that may
actually have benefit in HF-PEF.
The objective of the Alberta HEART program (http://
albertaheartresearch.ca) is to develop novel diagnostic,
therapeutic and prognostic approaches to patients with
HF-PEF. We hypothesize that novel imaging techniques
and biomarkers will aid in describing HF-PEF. Further-
more, the development of new diagnostic criteria will
allow us to: 1) better define the risk factors associated
with the HF-PEF; 2) elucidate the clinical, cellular and
molecular mechanisms involved with the development
and progression of HF-PEF; 3) design and test new
therapeutic strategies for patients with HF-PEF. Alberta
HEART additionally provides training and education
program for enhancing translational medicine, know-
ledge translation and clinical practice in heart failure.Methods/design
Trial status
The study is approved by the Health Research Ethics
Boards at the University of Alberta, Covenant Health and
the University of Calgary. Recruitment began in January
2010 and as of March 31, 2014, 649 patients have been
enrolled. ClinicalTrials.gov NCT02052804.
Study design
This is a prospective observational cohort study of
patients with, or at risk for, HF.
Study population
Patients are adults (i.e. aged over 18 years of age) re-
cruited from Alberta (population 4.0 million), principally
in Edmonton and Calgary but also from rural regions. In
order to enroll and study patients across the spectrum
of risk of developing HF, with signs or symptoms mim-
icking HF, or with a diagnosis of HF, a broad recruitment
strategy that categorizes patients into 5 distinct groups
is underway. The 5 distinct groups are:
1. High-risk of developing HF-PEF but no clinically
overt HF: Patients will have one or more of the
following: hypertension (≥3 medications or LVH on
ECG or left ventricular mass index > gender-matched
upper limit normal on an imaging test); diabetes (>45
years of age); atrial fibrillation; or obesity (body mass
index >30). Patients will be generally asymptomatic
(no dyspnea or fatigue) and have no known prior HF
or other cardiovascular disease.
2. High-risk of developing HF-PEF with other clinically
overt disease: Patients with other cardiovascular
diseases will be recruited including atrial fibrillation,
chronic coronary artery disease (including those
with a recent acute coronary syndrome > 2 weeks
prior), and COPD.
3. Patients with known HF-PEF: These are patients
who have been diagnosed with HF-PEF based on the
clinical phenotype of symptoms consistent with HF,
and a preserved ejection fraction. Patients with the
clinical diagnosis of HF-PEF and an ejection fraction >45%
will be enrolled in this study from the heart failure
clinics in Alberta. For further definition, the group will
be divided into 3a (LVEF always ≥ 45%; no right
ventricle involvement), 3b (LVEF previously <45%,
now ≥ 45%; with or without right ventricle
involvement), and 3c (LVEF always ≥ 45%; right
ventricle involvement or pulmonary hypertension
(TAPSE <16 mm, PASP > 35 mmHg, or clinical
judgment)).
4. Patients with known systolic HF: Patients with
systolic HF often have abnormalities in the
mechanical diastolic function and are necessary to
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group 3. An ejection fraction <45% and a diagnosis
of HF will be included.
5. Healthy age- and gender-matched controls:
Patients with no evidence of coronary artery disease,
hypertension, diabetes mellitus, organ disease or
replacement therapies; no evidence of inflammatory
or autoimmune conditions and not on cardiac
medications.
Patients will be recruited from HF and other clinics
across Alberta. Control patients are recruited through re-
ferrals from patients, clinicians and the broader commu-
nity across Alberta via public advertising, media events
and other public engagement. All patients signed informed
consent and the study is approved by the Health Research
Ethics Boards at the University of Alberta, Covenant
Health and the University of Calgary. After consent, pa-
tients are enrolled and undergo comprehensive clinical,
quality of life, biomarker, electrophysiologic and imaging
assessments (Figure 1). Patients are also eligible for sub-
study enrollment (see below). Patients are re-assessed at 6
and 12 months and longer-term clinical and outcome
surveillance is planned. Data is managed on the Alberta
Provincial Project for Outcome Assessment in Coronary
Heart Disease platform (http://www.approach.org/).
Adjudication
Given the lack of a single accepted and validated definition
for HF-PEF, the 3 most commonly used clinical criteria
from landmark papers [14-16] ongoing or completed trials
[17,18] or population studies [3,10,11] will be evaluated
for applicability to the development of new criteria
(Table 1). These criteria highlight two important points:Figure 1 Alberta HEART study design.(1) diagnostic uncertainty may exist and should be cap-
tured by any criteria proposed using a hierarchical meth-
odology; and (2) time of evaluation may alter the certainty
of the diagnosis as clinical findings (and non-invasive or
invasive markers) may change with therapy or time. In
addition, none of these 3 sets of criteria have been com-
pared, or evaluated in the setting of other conditions,
which may mimic symptoms of HF (e.g. lung disease,
hypertension, diabetes, obesity, deconditioning).
Each of the three definitions will be applied to the co-
hort in order to evaluate the sensitivity, specificity, diag-
nostic accuracy, positive predictive value and negative
predictive value using the diagnostic testing model based
on Bossuyt et al. [20] and Sackett and Haynes [21] and
the reporting methods endorsed by STARD [22] and
QUADAS-2 [23]. A reference standard for HF-PEF is
currently absent. Therefore, we have chosen to use a
consensus panel approach using a panel of adjudicators
blinded to the group of original recruitment (Figure 2).Phase 1
In the first phase, the adjudicators will be asked to group
the participants into one of the 5 groups above, using
pre-enrollment (i.e. no study related variables) clinical
criteria. We will then test the current definitions as to
their validity.
Phase 2
In the second phase, information from the study echo-
cardiogram and cardiac MRI will be used to re-
adjudicate participants and explore if the clinical
phenotype can be better enhanced using standardized
imaging biomarker information.
Table 1 Current diagnostic criteria for HF-PEF
Definition ESC [12,14] Vasan et al. [15] Zile et al. [16,19]
Signs or symptoms? Symptoms and signs of HF Symptoms and signs, supporting laboratory tests
and a typical clinical response to treatment#
Symptoms and signs of HF
(by Framingham criteria)
Ejection fraction LVEF > 50% and LVEDVI < 97 mls/m2 LVEF≥ 50% within 72 hours of HF event** LVEF > 50%
Echo/Cath/Biomarker evidence
of diastolic dysfunction?
Yes Yes*** Not required
Abnormal LV relaxation, filling, distensibility
indices on cardiac catheterization
#with diuretics, with or without documentation of elevated LV filling pressure (at rest, on exercise, or in response to a volume load) or a low cardiac index;
**downgraded to “Probable” if EF not defined in first 72 hours; ***downgraded to “Possible” if no Echo or Cath evidence; ESC, European Society of Cardiology.
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In the third phase, data from the clinical phenotype,
novel imaging markers, and biomarker testing to see if it
can identify distinct patient cohorts. This will also in-
corporate novel imaging or biomarkers that are emer-
ging or have not been previously validated.
Phase 4
In the final phase, all of the above will be integrated to
develop a de novo diagnostic system via a panel-based
method. Potential criteria will be viewed singly and to-
gether in order to develop a novel diagnostic scoring
system with the following principles: (1) clinical symp-
toms and signs must be included as a basis for the diag-
nosis of HF-PEF; (2) diagnostic certainty should be
categorized into definite, probable, possible, and not
present; (3) time of evaluation must be included with re-
spect to acute events; (4) no binary LVEF cutoff exists
therefore a spectrum of LVEF will be used; (5) areas to be
considered as candidate variables for evaluation should
include mechanical, electrical, biomarker, and imaging
modalities and should be done at rest and with provoca-
tion of exercise; (6) subtypes of HF-PEF likely exist based
on etiology or mechanism of dysfunction and these sub-
types likely include, but are not limited to, ventricular-Figure 2 Alberta HEART adjudication process.vascular decoupling, myocyte dysfunction, infiltration, valve-
related, extracellular matrix hypertrophy, post-operative
and arrhythmia-related, especially atrial fibrillation; and
(7) a simple clinical tool will be adopted if valid and clinic-
ally relevant, so attention to the end-user will be incorpo-
rated at an early stage through interaction with end-users
(see www.albertaheartresearch.ca). External validation
will be sought in existing datasets including MAGGIC,
CHARM and the Olmsted County database.
Imaging– MRI and echocardiography
Most diagnostic constructs for the identification of HF-PEF,
such as those from the European Society of Cardiology
(Table 1) [14], employ imaging-measures of diastolic func-
tion in a diagnostic algorithm. However, these are used as
binary variables and cut-points considered important for
the diagnosis of HF-PEF. Several new quantitative imaging
tests are available that more directly measure the physical
mechanisms during ventricular relaxation that are associ-
ated with diastolic function, such as ventricular untwisting
and global tissue strain rates, or that reflect tissue charac-
teristics including diffuse and focal fibrosis and edema.
Thus, our goal is to evaluate a wider array of imaging
tests for the purpose of defining a new set of practical
criteria for the characterization of diastolic dysfunction
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measures, main features will be evaluated using one or
both of echocardiographic and CMR imaging: (1) ven-
tricular stiffness [24,25]; (2) ventricular relaxation [24,26];
and (3) ventricular-vascular coupling [27,28]. This new ap-
proach will address the significant variability (often due to
load dependence) and low specificity of the conventional
imaging parameters of diastolic function and develop
load-independent measures.
In brief, the CMR scans will be performed on a 1.5 T
magnet (Sonata, Siemens and Avanto, Siemens) and will
include an assessment of: (1) atrial and ventricular vol-
umes and function using steady state free precession
(SSFP), (2) myocardial tissue characterization using late
gadolinium enhancement (LGE) as well as quantitative
T1 and T2 imaging, (3) estimation of ventricular and vas-
cular stiffness using SSFP, phase contrast and tagging tech-
niques and (4) pulmonary water content. For LGE and T1
imaging, 0.15 mmol/kg of gadolinium contrast (Gadovist,
Bayer) will be given intravenously. Cardiac volumes and
function and myocardial scar will be analyzed using com-
mercially available software (Syngo, Siemens and CMR42,
Circle) by experienced interpreters blinded to the study
group assignment. Other measures of cardiac function
and myocardial tissue characterization as well as vascular
function and pulmonary water content will be performed
using custom built software (MATLAB).
2D and 3D echocardiography will be performed on IE
33 (Philips) scanners with and without intravenous injec-
tion of the ultrasound contrast agent Definity. In addition,
recordings using color, spectral, tissue Doppler and
speckle tracking imaging will be obtained according to the
American Society of Echocardiography (ASE). The follow-
ing measurements will be performed by two experienced
observers according ASE standards: LV volumes, ejection
fraction, LA volumes, RV size and function, quantification
of valvular lesions, systolic pulmonary artery pressure, mi-
tral/tricuspid inflow velocities, mitral/tricuspid annular
velocities, global longitudinal strain and strain rate. The
recordings will also be processed using custom built soft-
ware for fusion of 3D datasets and new tools to assess
myocardial deformation which promise a more reliable as-
sessment of volume changes as well as systolic and dia-
stolic LV/RV function.
Exercise physiology substudy
A cardinal feature of HF, even when well compensated, is
decreased exercise capacity (VO2peak) that is due, in part, to
impaired cardiovascular and skeletal muscle that results in
reduced convective or diffusive O2 transport or decreased
O2 utilization by the active muscles [29,30]. Currently, no
study has prospectively examined the determinants of
exercise intolerance across the HF continuum (i.e.
healthy individuals and AHA/ACC stages A to C),therefore, uncertainty remains regarding the role that
abnormal cardiac, vascular or skeletal muscle function
play in limiting peak VO2 across the health, at risk and
HF continuum.
The goal of the substudy is to compare peak VO2 (and
its determinants) in healthy individuals, individuals at
risk for HF and clinically stable individuals with HF-REF
and HF-PEF. Subjects will be drawn from Groups 1 to 5
(above) and will undergo a cardiopulmonary exercise test
on a Lode (Groningen, NL) cycle ergometer (resting, with
15 W increase in peak power output every two minutes
until volitional exhaustion) with expired gas analysis and
inert gas rebreathing (Innocor CPX, Odense, DK) [31] to
measure peak VO2 and its Fick determinants (i.e. peak
heart rate, stroke volume, cardiac output, systemic vascu-
lar resistance, arterial-venous oxygen difference). We
will also use a non-invasive multisensory accelerometer
(SenseWear Armband) to measure Daily Energy Expend-
iture (DEE), which will provide information on how phys-
ical activity measurements relate to established prognostic
parameters. Assessing physical activity in patients doing
their usual activities allows for day-to-day fluctuations to
be taken into account. This will objectively assess daily
physical activity, sedentary time and energy expenditure
and compare these measures to established HF prognostic
parameters.
In addition, the role that vascular function (MRI-derived
aortic distensibility, brachial artery flow mediated dilation)
and ventricular-arterial coupling abnormalities may play
in limiting exercise performance will also be determined.
Vascular substudy
The endothelium plays a key role in vascular homeosta-
sis through the release of a variety of autocrine and
paracrine substances [32,33]. Dysfunction of endothelial
cells is a systemic process and the initiating event in ath-
erosclerosis. This has adverse effects on afterload and
ventricular-vascular mismatch may occur. Over the past
two decades it has been clearly demonstrated that subjects
with systolic dysfunction have impairment of endothelial
function. It was recently demonstrated that subjects with
HF-PEF did not have attenuated conduit vessel endothelial
dysfunction compared with age-matched controls [34].
Exercise training in this group improved VO2max but not
large vessel endothelial function [35]. However, another
group demonstrated attenuation of microvascular function
in a cohort with HF-PEF and was able to demonstrate an
association of microvascular function with outcomes [36].
We will recruit: (a) control subjects with no signs or
symptoms of HF; (b) subjects with HF and systolic dys-
function due to dilated cardiomyopathy (EF <35% and no
coronary artery disease) and no active vascular risk factors;
and (c) subjects with HF-PEF in Group 3 (above) and no
active vascular risk factors. Subjects will undergo the
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brachial flow-mediated dilation, b) hyperaemic velocity,
and c) finger-tip pulse arterial tonometry (PAT). These
measure conduit vessel endothelial function (FMD),
microvascular function (hyperaemic velocity), fingertip
small vessel endothelial function and capacitance (PAT).
Details of the methodology are well published and utilized
by our group [37,38].
Blood pressure wave substudy
Cardiac catheterization is indicated for clinical reasons in a
subset of patients enrolled into Alberta HEART. These pa-
tients will undergo an additional set of high fidelity simul-
taneous pressure and flow measurements using a combined
Doppler/Millar pressure wire (Combiwire®- Seimens) at 5
pre-specified locations in the aorta (vena contracta, mid-
aortic arch, distal to left subclavian, at the diaphragm and
infrarenal). Using this data, we will validate the Reservoir-
Pressure theory of pressure/flow propagation in humans
(already validated in large animal models). The successful
validation of this approach will enable us to predict, using a
derived mathematical formula, the effects of antihyperten-
sive agents (both existing and new) as well as future device
interventions upon individual pressure dynamics. We also
hope to determine characteristics of the pressure/volume
wave to potentially predict the development of future vas-
cular de-coupling and/or ventricular remodeling.
Biomarkers substudy
The use of biomarkers will allow us to screen high-risk
populations, to create a risk-prediction model in patients
with HF-PEF and to provide new insights into the patho-
physiology of HF-PEF. We hope to distinguish between
HF-PEF and HF-REF and to provide prognostic insight
into those with overt disease with the ultimate aim of pro-
viding tailored therapy to these different patient popula-
tions [39,40]. Importantly, we will be able to link these
data to important clinical outcomes such as mortality, sur-
vival free of heart transplantation, and hospitalizations.
These biomarkers will also be linked with our findings
from vascular physiology and imaging assessment. Serum,
plasma samples and whole blood will be collected and
stored for analysis in our core biomarker facilities. Bio-
marker testing will encompass both hypothesis-generating
and hypothesis-testing approaches. An “omics” platform
will be used, including microarray (mRNA and micro-
RNA), proteomics and metabolomics with a systems-based
analysis. A more tailored biomarker analysis of the extracel-
lular matrix, natriuretic peptides, inflammatory biomarkers
and other novel biomarkers will also be undertaken. We
will collaborate with the Prevention of Organ Failure
Centre of Excellence (PROOF; www.proofcentre.ca) at the
University of British Columbia, which is cross-disciplinary
team that unites scientific, technical, and commercializationexpertise in order to implement biomarkers to improve
management of heart, lung and kidney disease.
Risk substudy
Patients will undergo non-invasive risk evaluation using lo-
cally developed technology [41]. The technology is the
antithesis of a Holter monitor, as instead of randomly
acquiring data, signals are obtained during scripted in-
terventions designed to elicit physiologic transients, which
unmask physiologic defects in auto-regulation. Using this
data acquisition system, 2 metrics of risk of death were
discovered and partially validated. In contrast to the
current study, the original pilot study only recorded a sin-
gle bipolar ECG whereas we now record 6 standard ECG
leads. This will provide a better opportunity to examine
spatial heterogeneity of T wave alternans.
Clinical outcomes
Patients will have sequential testing including quality of
life and clinical outcomes over the first 12 months of study
entry. After that time, we will passively follow study partic-
ipants via linkage to external administrative databases held
by Alberta Health. Clinical outcomes of interest include
death, hospitalization, emergency department visits, phys-
ician resource use, and/or heart transplant. Patients will
be followed for a total of 5 years of follow-up.
Recognizing that our prospectively-enrolled cohort will
be subject to selection and referral biases, we also plan
to use administrative data maintained by Alberta Health
and Alberta Health Services to explore health service
use and outcomes in all Albertans with HF. This will be
used in two ways:
1. Patients who have provided consent in the
prospectively collected cohort will be tracked
longitudinally to capture all of their interactions
with the healthcare system.
2. Anonymized data obtained from Alberta Health will
be used to explore the in-patient, out-patient,
emergency department, medications and outcomes
of all patients with HF using techniques previously
validated by our group [1,5,42,43].
These complementary approaches will allow for appro-
priate comparisons of patient-, provider- and system-level
variables that may vary across the spectrum of HF or those
patients at risk for HF.
Sample size
Alberta HEART plans to recruit 700 patients with up to
100 patients in each of Groups 1, 2 and 5 and 200 patients
in each of Groups 3 (HF-PEF) and 4 (known systolic HF).
Given the lack of validated data from which to calculate a
sample size, a convenience sampling technique has been
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ercise, biomarkers) the HEART study will be significantly
powered, but for other outcomes (e.g. clinical outcomes)
HEART will be underpowered. Nevertheless, the sample
size will be increased as appropriate to meet the primary
objectives of the study. An additional 100 age- and gender-
matched controls (matched to group 3) will be been re-
cruited and tested. Recruitment began in January 2010
and as of March 31st, 2014, 649 participants have been
enrolled.
Training program
Alberta HEART has a training program (Supporting
Training Encompassing All in Diastolic Heart Failure
[STEADi HF]) to train researchers of all backgrounds and
across all 4 pillars of research as described by the Canadian
Institutes of Health Research (www.cihr.ca). These com-
petitive training grants are awarded to trainees who are
researching an area of heart failure and are collaborating
with/mentored by another team member. This will assist
in the building of interdisciplinary partnerships along with
providing the trainee with a clearer understanding of the
research skills in another discipline.
Discovery science
Of a total of 24 investigators, Alberta HEART includes 8
scientists who have a primary focus on traditional funda-
mental discovery science. The project also incorporates as-
pects important for translational science: development of
an appropriate animal model from which to test novel
therapeutics before first-in-man studies; studying the tis-
sue, cellular and sub-cellular interactions that may be re-
lated to a clinical phenotype; and exploring proteomic,
metabolomic and genomic pathways to understand overall
cardiac function.
Discussion
Alberta HEART has the primary objective to define new
diagnostic criteria for patients with HF-PEF. New criteria
will allow for targeted therapies, diagnostic tests and
further understanding of the patients, both at-risk for
and with heart failure. Interaction across pillars of re-
search and with clinicians, patients, the public and policy
makers is embedded within this project to ensure accurate
and timely translation of new and existing knowledge for
the prevention, diagnosis and treatment of patients with
cardiovascular disease.
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